HC Wainwright Cuts Earnings Estimates for Vir Biotechnology

Vir Biotechnology, Inc. (NASDAQ:VIR) – Research analysts at HC Wainwright lowered their FY2028 EPS estimates for shares of Vir Biotechnology in a report released on Wednesday, October 7th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.71) per share for the year, down from their prior forecast of ($1.70). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Vir Biotechnology’s FY2029 earnings at ($1.26) EPS and FY2030 earnings at ($0.29) EPS.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.14. The firm had revenue of $238.95 million during the quarter, compared to the consensus estimate of $135.88 million. The business’s revenue was up 19582.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.80) EPS.

Other equities research analysts have also issued research reports about the stock. Raymond James Financial reiterated a “strong-buy” rating on shares of Vir Biotechnology in a research note on Monday, September 28th. Morgan Stanley set a $25.00 target price on Vir Biotechnology in a research note on Thursday, August 6th. Wall Street Zen raised Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Friday, October 2nd. Finally, Zacks Research lowered Vir Biotechnology from a “hold” rating to a “strong sell” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.86.

Vir Biotechnology Stock Performance

Vir Biotechnology stock opened at $11.12 on Friday. Vir Biotechnology has a fifty-two week low of $4.82 and a fifty-two week high of $11.94. The stock has a market cap of $1.88 billion, a PE ratio of -5.98 and a beta of 1.59. The firm’s 50-day simple moving average is $10.41 and its 200 day simple moving average is $9.78.

Institutional Trading of Vir Biotechnology

A number of large investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC bought a new stake in Vir Biotechnology in the second quarter worth about $25,034,000. Parkman Healthcare Partners LLC bought a new position in shares of Vir Biotechnology during the 2nd quarter valued at approximately $4,843,000. ARCH Venture Management LLC bought a new position in shares of Vir Biotechnology during the 2nd quarter valued at approximately $129,353,521. Pictet Asset Management Holding SA grew its position in shares of Vir Biotechnology by 10,878.9% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company’s stock valued at $13,268,000 after acquiring an additional 1,467,340 shares during the period. Finally, Candriam S.C.A. increased its stake in shares of Vir Biotechnology by 10.1% during the 1st quarter. Candriam S.C.A. now owns 1,135,763 shares of the company’s stock worth $10,176,000 after purchasing an additional 104,100 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Trending Headlines about Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Higher price target and Buy rating: HC Wainwright raised its price target for Vir Biotechnology from $20 to $22 and reiterated a Buy rating, implying substantial potential upside from the current level. The upgrade reflects optimism about Vir’s pipeline and upcoming clinical catalysts. Vir Biotechnology stock gained before SOLSTICE data
• Positive Sentiment: New chief medical officer: Vir appointed David Liu as chief medical officer, strengthening its clinical-development leadership ahead of important data readouts. The appointment may improve investor confidence in execution across the company’s infectious-disease programs. Vir appoints David Liu as chief medical officer
• Neutral Sentiment: SOLSTICE data is the key catalyst: Upcoming Phase 2 SOLSTICE results in HDV could materially reshape Vir’s investment narrative. Positive efficacy or safety data could support the pipeline and valuation, while disappointing results could increase development and financing concerns. No results have been reported yet. Upcoming SOLSTICE Phase 2 HDV data
• Neutral Sentiment: A financial comparison of uniQure and Vir Biotechnology provides sector context but does not appear to introduce a new company-specific catalyst. uniQure and Vir Biotechnology financial survey
• Negative Sentiment: Zacks downgrade: Zacks Research lowered Vir Biotechnology from “Hold” to “Strong Sell.” The downgrade is likely weighing on the stock because it reinforces concerns about the company’s continuing losses and reliance on future clinical success. Vir Biotechnology stock rating lowered by Zacks Research

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing treatments and preventive therapies for serious infectious diseases. The company uses immunologic insights, antibody technology, cellular approaches and other scientific platforms to address diseases in which the immune system plays a central role.

Vir’s research and development programs have included therapies for chronic hepatitis B, influenza, human immunodeficiency virus (HIV) and COVID-19. Its pipeline has included investigational antibody and immunomodulatory candidates such as tobevibart and elebsiran for hepatitis B, as well as programs designed to prevent or treat other viral infections.